Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Clinical Characteristics and Treatment Patterns Among Patients Diagnosed With Cluster Headache in U.S. Healthcare Claims Data.

Choong CK, Ford JH, Nyhuis AW, Joshi SG, Robinson RL, Aurora SK, Martinez JM.

Headache. 2017 Oct;57(9):1359-1374. doi: 10.1111/head.13127. Epub 2017 Jun 5.

2.

Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention-Deficit/Hyperactivity Disorder.

Clemow DB, Nyhuis AW, Robinson RL.

CNS Neurosci Ther. 2016 Dec;22(12):970-978. doi: 10.1111/cns.12595. Epub 2016 Jul 31.

3.

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.

Faries D, Ascher-Svanum H, Phillips G, Nyhuis AW, Sugihara T, Stauffer V, Kinon BJ.

BMC Med Res Methodol. 2012 Sep 13;12:142. doi: 10.1186/1471-2288-12-142.

4.

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians.

Chen J, Ascher-Svanum H, Nyhuis AW, Case MG, Phillips GA, Schuh KJ, Hoffmann VP.

Patient Prefer Adherence. 2011;5:547-54. doi: 10.2147/PPA.S23255. Epub 2011 Nov 3.

5.

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.

Ascher-Svanum H, Zhao F, Detke HC, Nyhuis AW, Lawson AH, Stauffer VL, Montgomery W, Witte MM, McDonnell DP.

BMC Psychiatry. 2011 Sep 23;11:152. doi: 10.1186/1471-244X-11-152.

6.

Predictors of switching antipsychotic medications in the treatment of schizophrenia.

Nyhuis AW, Faries DE, Ascher-Svanum H, Stauffer VL, Kinon BJ.

BMC Psychiatry. 2010 Sep 28;10:75. doi: 10.1186/1471-244X-10-75.

7.

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia.

Ascher-Svanum H, Nyhuis AW, Faries DE, Ball DE, Kinon BJ.

BMC Psychiatry. 2010 Jan 28;10:11. doi: 10.1186/1471-244X-10-11.

8.

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia.

Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ.

BMC Psychiatry. 2009 Sep 2;9:54. doi: 10.1186/1471-244X-9-54.

9.

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example.

Faries DE, Nyhuis AW, Ascher-Svanum H.

Cost Eff Resour Alloc. 2009 May 27;7:11. doi: 10.1186/1478-7547-7-11.

10.

Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia.

Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A.

Schizophr Bull. 2008 Nov;34(6):1163-71. Epub 2007 Dec 21.

11.

The learning curve and the cost of heart transplantation.

Woods JR, Saywell RM Jr, Nyhuis AW, Jay SJ, Lohrman RG, Halbrook HG.

Health Serv Res. 1992 Jun;27(2):219-38.

Supplemental Content

Loading ...
Support Center